It’s hard to turn on the TV these days without seeing ads for drugs like Ozempic, Wegovy, Zepbound or Mounjaro. These ...

For kidney transplant recipients with type 2 diabetes, use of glucagon-like peptide-1 receptor agonists was associated with ...

GLP-1 therapy is a groundbreaking approach in the treatment of obesity and metabolic health issues. GLP-1, or glucagon-like ...

The rise of GLP-1s (glucagon-like peptides) has revolutionized obesity management. These medications help people shed pounds ...

Roche plans to develop a combination therapy of petrelintide alongside GLP-1 and the glucose-dependent insulinotropic polypeptide (GIP), which simultaneously stimulates insulin secretion. They stated ...

Retatrutide mimics the effects of naturally occurring gut hormones to improve metabolic health. Stimulating insulin release ...

The two companies will work together on Zealand’s amylin analogue petrelintide as a monotherapy and in combination therapies.

It works by mimicking a hormone called glucagon-like peptide-1, or GLP-1, which stimulates the body’s production of insulin.

The National Institutes of Health focuses on nucleotides, not narratives—but both must be an essential part of its mission.

Despite the promising results, further research is needed before GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists ...

A new weight loss treatment, Sirona, expands in the stomach to curb hunger. Phase 2 trials show promising results and the ...

Researchers analysed data from 150 adults with T1D, divided into semaglutide, tirzepatide, and control groups.